MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, BCYC had -$73,126K decrease in cash & cash equivalents over the period. -$71,847K in free cash flow.

Cash Flow Overview

Change in Cash
-$73,126K
Free Cash flow
-$71,847K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Net loss
-59,100 -139,706
Share-based compensation expense
8,771 19,040
Depreciation and amortization
1,756 3,330
Deferred income tax benefit
-46 -1,647
Research and development incentives receivable
7,614 20,781
Prepaid expenses and other assets
1,375 8,571
Operating lease rightofuse assets
-1,172 -2,235
Accounts payable
-5,070 1,080
Accrued expenses and other current liabilities
1,121 972
Operating lease liabilities
-1,390 -2,656
Deferred revenue
-9,398 -12,452
Net cash used in operating activities
-71,173 -159,156
Purchases of property and equipment
674 1,102
Net cash used in investing activities
-674 -1,102
Proceeds from the exercise of share options and settlement of restricted share units
1 3
Payments of finance lease obligations
31 89
Net cash (used in) provided by financing activities
-30 -86
Effect of exchange rate changes on cash, cash equivalents and restricted cash
-1,249 2,275
Net (decrease) increase in cash, cash equivalents and restricted cash
-73,126 -158,069
Cash and cash equivalents at beginning of period
880,067 -
Cash and cash equivalents at end of period
648,872 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

BICYCLE THERAPEUTICS PLC (BCYC)

BICYCLE THERAPEUTICS PLC (BCYC)